Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài:Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study | Journal of Occupational Medicine and Toxicology BioMed Central Research Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma an observational study Athanasios Xanthopoulos Torsten T Bauer Torsten G Blum Jens Kollmeier Nicolas Schonfeld and Monika Serke Address Respiratory Diseases Clinic Heckeshorn Department of Pneumology HELIOS Klinikum Emil von Behring Berlin Germany Email Athanasios Xanthopoulos - Torsten T Bauer - Torsten G Blum - Jens Kollmeier - Nicolas Schonfeld - Monika Serke - Corresponding author Open Access Published 18 December 2008 Received 9 September 2008 . . . _ . Accepted 18 December 2008 Journal of Occupational Medicine and Toxicology 2008 3 34 doi l745-6673-3-34 This article is available from http content 3 1 34 2008 Xanthopoulos et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The aim of this study was to investigate the efficacy and safety of oxaliplatin gemcitabine in patients with diffuse malignant pleural mesothelioma MPM pretreated with pemetrexed. Methods The study enrolled consecutive patients with relapsed MPM all of them pretreated with a platin-pemetrexed-based chemotherapy. Oxaliplatin 80 mg m2 was administered as monotherapy or in combination with gemcitabine 1000 mg m2 given on day 1 and 8. Cycles were repeated every 21 days. The primary endpoints were response rate and disease control rate. Secondary endpoints included overall survival OS time to tumour progression TTP .
